Camellia. API's fortunes could be turning

The fortunes of Australia Pharmaceutical Industries (API), at Camellia, could be turning, compared with its competitor, Sigma Pharmaceutical, after API’s first-half result convinced several brokers the worst may be over for the drug distributor, according to The Australian Financial Review. APO posted flat revenue and underlying net profit that excludes one-off costs of $1.85 billion and $11.2 million respectively.

Camellia. API into insurance for women

Fierce competition from the big supermarket chains and a strong customer loyalty program have prompted Australian Pharmaceutical Industries’ (API) Priceline retail chain to step into the insurance sector, according to The Australian Financial Review. The first products from API’s agreement with AIA Insurance were introduced last week and are aimed squarely at women. Priceline’s research found women were “chronically under-insured” Policies start at $20 a month.

Camellia. API to recruit more franchises

Australian Pharmaceutical Industries (API), based at Camellia, expects to recruit more than 100 new franchises to join the company’s Priceline pharmacy network this year. Since 2004, the Priceline and Priceline Pharmacy network has grown to more than 300 stores.

Camellia API to roll out plan

A plan by Australian Pharmaceutical Industries, based at Camellia, to accelerate the roll-out of its Priceline beauty and healthcare stores to hit a target of 500 shops in the near term, comes as it claims to have taken market share from the supermarkets and hooked 3.2 million members into its loyalty club.

Camellia. API struggles with competition

Australian Pharmaceutical Industries, based at Camellia, is battling several difficulties including lower retail spending and increasing competition in wholesaling and the health and beauty sector. API CEO, Stephen Roche, said in The Australian Financial Review, the company will adapt to the changing industry landscape in order to protect margins.

API seeks to consolidate the market

Australian Pharmaceutical Industries (API), headquartered at Camellia, is interested in acquiring the vitamins and wholesale drug distribution of Primary Health Care. “We’ve always said we supported consolidation in the pharmaceutical market,” said MD, Stephen Roche. API delivered a first-half net profit of $6.15 million to February. The company’s supply chain is undergoing a three-year reorganisation which will cost $60 million and deliver annual savings of $18 million from 2011.